This paper examines the country's potential as a strategic location for metabolic clinical research. This white paper explores the burden of obesity, type 2 diabetes mellitus (T2DM), cardiometabolic disorders, MASLD and MASH in the Philippines, alongside the clinical, operational and regulatory factors that support successful trial delivery.

Drawing on investigator insights and operational experience, the paper highlights the Philippines' access to treatment-naïve and undertreated patient populations, established late-phase clinical trial capabilities, globally aligned research standards, broad diagnostic availability, and growing site network. It also discusses patient recruitment considerations, site readiness, regulatory pathways, quality oversight, and emerging opportunities in cardiometabolic, obesity, MASLD and MASH clinical development.